相关实验视频

Updated: Aug 3, 2026

Transduction of Human Cells with Polymer-complexed Ecotropic Lentivirus for Enhanced Biosafety

Transduction of Human Cells with Polymer-complexed Ecotropic Lentivirus for Enhanced Biosafety

Published on: July 24, 2011

使用PKC激动剂增强治疗性晶状病毒载体的标位

Charles Moore-Kelly¹, Rajesh Reddem¹, Ben M Alberts¹

¹Oxford Biomedica (UK) Ltd., Windrush Court, Transport Way, Oxford OX4 6LT, UK.

Molecular therapy. Methods & clinical development

|June 10, 2025

概括

蛋白质激酶C (PKC) 激动剂通过促进基因表达和颗粒释放,显著增强了lentiviral vector (LV) 的产生. 这种方法提高了治疗性基因疗法的制造效率,并降低了成本.

科学领域:

基因治疗基因治疗
分子生物学分子生物学
生物技术是生物技术.

背景情况:

静脉病毒载体 (LV) 对于基因疗法至关重要,它利用HIV-1机制实现稳定的基因整合.
目前基于HEK293T的生产系统面临着低于最佳的LV成分表达的挑战,限制了治疗开发.
高效的LV生产对于将基因疗法推向临床应用至关重要.

研究的目的:

为了确定增强病毒载体 (LV) 生产标位的新方法.
调查蛋白激酶C (PKC) 激动剂在改善LV制造中的作用.
评估PKC激动剂和U1 snRNA增强剂对LV产生的联合作用.

主要方法:

用蛋白激酶C (PKC) 激动剂刺激HEK293T细胞.
对LV基因组RNA转录和载体粒子释放动力学的分析.
评估AP-1转录因子子子单位上调和NF-κB通路独立性.
用甲酸盐 (HDAC抑制剂) 和U1 snRNA增强剂进行组合治疗.
定量化仿制抗原受体 (CAR) -LV标位和颗粒与传染性比.

主要成果:

PKC激活导致了快速的LV基因组RNA转录和加速的载体粒子释放.
治疗PKC激动剂导致CAR-LV标位增加了约3倍.
将PKC激动剂与U1 snRNA增强剂相结合,可以实现LV标位增加约9倍.
使用PKC激动剂制造的LV保持了可比的颗粒感染率和T细胞转导效率.

结论:

PKC激动剂代表了一种强大的策略,用于增强晶状病毒载体 (LV) 生产.
这种诱导方法补充了现有的策略,如HDAC抑制.
这些发现表明,PKC激动剂可以显著提高基因疗法LV制造的成本效益.

关键词:

制造业 LV 制造业在 PKC PKC 中,你会发现.这是一种PKC激动剂,PKC激动剂.基于U1 snRNA的隐形病毒载体增强剂生物处理生物处理.仿制性抗原受体T细胞疗法T细胞疗法基因治疗的基因疗法这是一个lentiviral向量.蛋白质激酶 C 的蛋白质激酶 C.

更多相关视频

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

相关概念视频

PCR - Polymerase Chain Reaction

PCR - Polymerase Chain Reaction

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...